
someday is today



Last year alone, LLS invested nearly \$74 million in cutting-edge research.

For more than 60 years LLS has invested more than \$1 billion to advance cancer therapies and save lives. Nearly 40% of new cancer therapies approved by the FDA between 2000 and 2013 were first approved for blood cancer patients.

LLS has
helped advance
laws in more than
half of the states
to ensure coverage
and payment parity
for cancer medications,
regardless of
how or where
administered.

Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled or even quadrupled.

In 1964, the five-year survival rate for children with with the most commonly diagnosed leukemia was 3%. Today it's approximately 90%.

Since LLS's inception 65 years ago, cures for many patients with acute lymphoblastic leukemia and Hodgkin lymphoma have been achieved.


Hodgkin lymphoma survival rates more than doubled, to 87%, since the 1960s.

The survival rate for myeloma more than tripled since the 1960s.

LLS helped advance targeted therapies for patients with chronic myeloid leukemia; this oral drug is now helping patients with other cancers. LLS-funded research teams at multiple institutions are testing different approaches to activate the immune system to kill cancer cells.

LLS-funded teams have helped advance FDA-approved targeted therapies to treat patients with chronic lymphocytic leukemia and other B-cell cancers. LLS-funded researchers helped advance an antibody therapy that helps boost the immune system to attack cancer cells in patients with lymphoma and chronic lymphocytic leukemia.

LLS partners with academic centers and biotechnology companies to get new treatments to more patients, faster. LLS advocates for state and federal legislation to ensure patients have access to quality, affordable and coordinated care.



Today we are closer than ever to cures for many kinds of blood cancers. We are at the brink of life-changing breakthroughs. We can see the end of cancer from here. Join us.

